arrow
S

Secondo Folli

Fondazione IRCCS Istituto Nazionale dei Tumori
H指数:27
被引数:2,603

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adjuvant chemotherapy in stage I triple-negative breast cancer: A systematic review and meta-analysis of survival outcomes

I期三阴性乳腺癌的辅助化疗:生存结局的系统评价与Meta分析

2026-05-140
PRE
Regional anesthesia in breast surgery: An Italian expert consensus - Part 1: Methodology and Delphi strategy

乳腺癌手术中的区域麻醉:意大利专家共识——第一部分:方法学与德尔菲策略

2026-01-010
PRE
Sentinel Node Biopsy Alone Versus Sentinel Node Biopsy Plus Axillary Dissection in cT2 cN0/1 Breast Cancer After Neoadjuvant Chemotherapy: 15-Year Results of a Prospective Interventional Study

cT2 cN0/1乳腺癌新辅助化疗后,仅行哨兵淋巴结活检与哨兵淋巴结活检联合腋窝清扫的比较:一项前瞻性干预研究的15年结果

2025-11-180
PRE
Health-related quality of life and fear of recurrence after early breast cancer treatment: results from a cross-sectional survey

健康相关生活质量及治疗后复发恐惧:一项横断面调查的结果

2025-11-130
OAAI
Fat grafting is oncologically safe during implant-based breast reconstruction and mastectomy after radiotherapy for breast cancer or Hodgkin Lymphoma: results of a multicentric study
2024-05-020
PRE
Precocious modulation of metabolic and immunological parameters predicts tumor response to fastingmimicking diet plus chemotherapy in patients with early stage TNBC
2024-05-021
PRE
Oncoplastic and reconstructive surgery in SENONETWORK Italian breast centers: lights and shadows
BREAST
IF7.9
2024-02-010
OAAI
Is routine axillary lymph node dissection needed to tailor systemic treatments for breast cancer patients in the era of molecular oncology? A position paper of the Italian National Association of Breast Surgeons (ANISC)
EJSO
IF2.9
2024-02-014
OAAI
Low neutrophil-to-lymphocyte ratio and pan-immune-inflammation-value predict nodal pathologic complete response in 1274 breast cancer patients treated with neoadjuvant chemotherapy: a multicenter analysis
2023-09-156
OAAI
Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world

将HER2-low乳腺癌预测和预后数据从临床试验转移到现实世界

2022-09-2619
OAAI
The impact of COVID-19 on diagnosis of recurrent breast cancer
2022-02-150
PRE